More direct evidence for a malonyl-CoA-carnitine palmitoyltransferase I interaction as a key event in pancreatic beta-cell signaling.
We sought to explore the emerging concept that malonyl-CoA generation, with concomitant suppression of mitochondrial carnitine palmitoyltransferase I (CPT I), represents an important component of glucose-stimulated insulin secretion (GSIS) by the pancreatic beta-cell (Prentki M, Vischer S, Glennon MC, Regazzi R, Deeney JT, Corkey BE: Malonyl-CoA and long-chain acyl-CoA esters as metabolic coupling factors in nutrient-induced insulin secretion. J Biol Chem 267:5802-5810, 1992). Accordingly, pancreases from fed rats were perfused with basal (3 mM) followed by high (20 mM) glucose in the absence or presence of 2 mM hydroxycitrate (HC), an inhibitor of ATP-citrate (CIT) lyase (the penultimate step in the glucose-->malonyl-CoA conversion). HC profoundly inhibited GSIS, whereas CIT had no effect. Inclusion of 0.5 mM palmitate in the perfusate significantly enhanced GSIS and completely offset the negative effect of HC. In isolated islets, HC stimulated [1-14C]palmitate oxidation in the presence of basal glucose and markedly obtunded the inhibitory effect of high glucose. Directional changes in 14C incorporation into phospholipids were opposite to those of 14CO2 production. At a concentration of 0.2 mM, 2-bromostearate, 2-bromopalmitate and etomoxir (all CPT I inhibitors) potentiated GSIS by the pancreas and inhibited palmitate oxidation in islets. However, at 0.05 mM, etomoxir did not influence insulin secretion but still caused significant suppression of fatty acid oxidation. The results provide more direct evidence for a pivotal role of malonyl-CoA suppression of CPT I, with attendant elevation of the cytosolic long-chain acyl-CoA concentration, in GSIS from the normal pancreatic beta-cell.(ABSTRACT TRUNCATED AT 250 WORDS)
Department of Internal Medicine, Gifford Laboratories, University of Texas Southwestern Medical Center at Dallas 75235-8858.
S
S
Chen
A
A
Ogawa
M
M
Ohneda
R H
RH
Unger
D W
DW
Foster
J D
JD
McGarry
D001275:ATP Citrate (pro-S)-Lyase / Q000037:antagonists & inhibitors; D000818:Animals; D002334:Carnitine O-Palmitoyltransferase / Q000037:antagonists & inhibitors / Q000378:metabolism*; D002951:Citrates / Q000494:pharmacology; D004852:Epoxy Compounds / Q000494:pharmacology; D005947:Glucose / Q000494:pharmacology; D007004:Hypoglycemic Agents / Q000494:pharmacology; D066298:In Vitro Techniques; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000187:drug effects / Q000201:enzymology / Q000502:physiology*; D007700:Kinetics; D008297:Male; D008316:Malonyl Coenzyme A / Q000378:metabolism; D010168:Palmitates / Q000494:pharmacology; D019308:Palmitic Acid; D010169:Palmitic Acids / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D015398:Signal Transduction; D013229:Stearic Acids / Q000494:pharmacology; D013997:Time Factors
D002951:Citrates; D004852:Epoxy Compounds; D007004:Hypoglycemic Agents; D007328:Insulin; D010168:Palmitates; D010169:Palmitic Acids; D013229:Stearic Acids; C000320:2-bromostearic acid; C022776:2-bromopalmitate; D019308:Palmitic Acid; D008316:Malonyl Coenzyme A; C007999:hydroxycitric acid; D002334:Carnitine O-Palmitoyltransferase; D001275:ATP Citrate (pro-S)-Lyase; D005947:Glucose; C054207:etomoxir